137 related articles for article (PubMed ID: 20109515)
1. Synthesis and evaluation of conformationally constrained peptide analogues as the Src SH3 domain binding ligands.
Tiwari R; Brown A; Narramaneni S; Sun G; Parang K
Biochimie; 2010 Sep; 92(9):1153-63. PubMed ID: 20109515
[TBL] [Abstract][Full Text] [Related]
2. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding.
Nam NH; Ye G; Sun G; Parang K
J Med Chem; 2004 Jun; 47(12):3131-41. PubMed ID: 15163193
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
Pisabarro MT; Serrano L; Wilmanns M
J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566
[TBL] [Abstract][Full Text] [Related]
4. Identification and specificity studies of small-molecule ligands for SH3 protein domains.
Inglis SR; Stojkoski C; Branson KM; Cawthray JF; Fritz D; Wiadrowski E; Pyke SM; Booker GW
J Med Chem; 2004 Oct; 47(22):5405-17. PubMed ID: 15481978
[TBL] [Abstract][Full Text] [Related]
5. Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications.
Polverini E; Rangaraj G; Libich DS; Boggs JM; Harauz G
Biochemistry; 2008 Jan; 47(1):267-82. PubMed ID: 18067320
[TBL] [Abstract][Full Text] [Related]
6. The C-terminal SH3 domain of the adapter protein Grb2 binds with high affinity to sequences in Gab1 and SLP-76 which lack the SH3-typical P-x-x-P core motif.
Lewitzky M; Kardinal C; Gehring NH; Schmidt EK; Konkol B; Eulitz M; Birchmeier W; Schaeper U; Feller SM
Oncogene; 2001 Mar; 20(9):1052-62. PubMed ID: 11314042
[TBL] [Abstract][Full Text] [Related]
7. Prediction of binding affinities between the human amphiphysin-1 SH3 domain and its peptide ligands using homology modeling, molecular dynamics and molecular field analysis.
Hou T; McLaughlin W; Lu B; Chen K; Wang W
J Proteome Res; 2006 Jan; 5(1):32-43. PubMed ID: 16396493
[TBL] [Abstract][Full Text] [Related]
8. SH3 domains and drug design: ligands, structure, and biological function.
Dalgarno DC; Botfield MC; Rickles RJ
Biopolymers; 1997; 43(5):383-400. PubMed ID: 9566119
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous assay of Src SH3 and SH2 domain binding using different wavelength fluorescence polarization probes.
Lynch BA; Minor C; Loiacono KA; van Schravendijk MR; Ram MK; Sundaramoorthi R; Adams SE; Phillips T; Holt D; Rickles RJ; MacNeil IA
Anal Biochem; 1999 Nov; 275(1):62-73. PubMed ID: 10542110
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics.
Oishi S; Karki RG; Kang SU; Wang X; Worthy KM; Bindu LK; Nicklaus MC; Fisher RJ; Burke TR
J Med Chem; 2005 Feb; 48(3):764-72. PubMed ID: 15689160
[TBL] [Abstract][Full Text] [Related]
11. Differential ligand recognition by the Src and phosphatidylinositol 3-kinase Src homology 3 domains: circular dichroism and ultraviolet resonance Raman studies.
Okishio N; Tanaka T; Fukuda R; Nagai M
Biochemistry; 2003 Jan; 42(1):208-16. PubMed ID: 12515556
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs.
Romir J; Lilie H; Egerer-Sieber C; Bauer F; Sticht H; Muller YA
J Mol Biol; 2007 Feb; 365(5):1417-28. PubMed ID: 17118402
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of the SH3 domain of betaPIX in complex with a high affinity peptide from PAK2.
Hoelz A; Janz JM; Lawrie SD; Corwin B; Lee A; Sakmar TP
J Mol Biol; 2006 Apr; 358(2):509-22. PubMed ID: 16527308
[TBL] [Abstract][Full Text] [Related]
14. Automated Fmoc-based solid-phase synthesis of peptide thioesters with self-purification effect and application in the construction of immobilized SH3 domains.
Mende F; Beisswenger M; Seitz O
J Am Chem Soc; 2010 Aug; 132(32):11110-8. PubMed ID: 20662535
[TBL] [Abstract][Full Text] [Related]
15. Recognition of lysine-rich peptide ligands by murine cortactin SH3 domain: CD, ITC, and NMR studies.
Rubini C; Ruzza P; Spaller MR; Siligardi G; Hussain R; Udugamasooriya DG; Bellanda M; Mammi S; Borgogno A; Calderan A; Cesaro L; Brunati AM; Donella-Deana A
Biopolymers; 2010; 94(3):298-306. PubMed ID: 19921743
[TBL] [Abstract][Full Text] [Related]
16. Design of tetrapeptide ligands as inhibitors of the Src SH2 domain.
Nam NH; Pitts RL; Sun G; Sardari S; Tiemo A; Xie M; Yan B; Parang K
Bioorg Med Chem; 2004 Feb; 12(4):779-87. PubMed ID: 14759738
[TBL] [Abstract][Full Text] [Related]
17. Interactions between the Fyn SH3-domain and adaptor protein Cbp/PAG derived ligands, effects on kinase activity and affinity.
Solheim SA; Petsalaki E; Stokka AJ; Russell RB; Taskén K; Berge T
FEBS J; 2008 Oct; 275(19):4863-74. PubMed ID: 18721137
[TBL] [Abstract][Full Text] [Related]
18. Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase.
Siegal G; Davis B; Kristensen SM; Sankar A; Linacre J; Stein RC; Panayotou G; Waterfield MD; Driscoll PC
J Mol Biol; 1998 Feb; 276(2):461-78. PubMed ID: 9512716
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
Brasher BB; Roumiantsev S; Van Etten RA
Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
[TBL] [Abstract][Full Text] [Related]
20. The identification of conserved interactions within the SH3 domain by alignment of sequences and structures.
Larson SM; Davidson AR
Protein Sci; 2000 Nov; 9(11):2170-80. PubMed ID: 11152127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
